Guest guest Posted October 30, 2006 Report Share Posted October 30, 2006 - Skinny alienoverlords ; armageddon-or-newage ; astronautcreationofman ; ctrl ; DavidIcke ; HAL838 ; IUFO ; NewRealmsLightMultidimensionHiddenRealms ; openmindfiles ; TheMulti-DimensionalNewsPortal ; TheNeuschwabenlandTimes Monday, October 30, 2006 4:33 PM IUFO: Alan Cantwell MD On The Bacterial Cause Of Cancer-The Cancer Bacteria Forum CANTWELL Alan Cantwell MD On The Bacterial Cause Of Cancer The Cancer Bacteria Forum An interview with Dr. Alan Cantwell MD by Ron Falcone10-28-6 EDITOR'S NOTE: Dr. Alan Cantwell has investigated the phenomenon of cancer bacteria for over thirty years. A graduate of New York Medical College, doctor Cantwell completed a residency program in dermatology at Long Beach Veteran's Administration Hospital in Long Beach, CA and then practiced in the dermatology department of Kaiser-Permanente in Hollywood, California, from 1965 until his retirement in 1994. Dr. Cantwell is the author of more than thirty published papers on breast cancer, lymphoma, Kaposi's sarcoma, Hodgkin's disease, lupus, scleroderma, AIDS, and other immunological diseases. These papers have appeared in many peer reviewed journals, including Growth, International Journal of Dermatology, Journal of Dermatologic Surgery and Oncology and Archives of Dermatology. He is also a prolific author (see Aries Rising Press for a list of his titles). This interview was conducted by Ron Falcone on October 24, 2006 The Interview CBH: Hi Dr. Cantwell and thanks very much for joining us today at the Cancer Bacteria Homepage. It is an honor having you visit with us. To begin, can you tell us how long you have been a physician and what your specialty was before becoming interested in cancer bacteria research? Cantwell : I received my MD degree from New York Medical College in 1959. After an internship at Mercy Hospital in San Diego, I served as a Captain in the Army Medical Corps for two years in post-war Korea, and later began a three-year dermatology residency program at the VA in Long Beach, CA, in 1962. In the fall of 1963 I read a medical report concerning tuberculosis-type infections of the skin following prescribed injections of vaccines and antibiotics. This quickly led me to investigate unusual cases of "panniculitis" (an inflammation of the fat) in several of my VA patients who had injections. I was able to show these patients were infected with peculiar and unusual "acid-fast" bacteria. This was reported in The Archives of Dermatology in 1966. My panniculitis work segued into scleroderma research where I was also able to show acid-fast, TB-like bacteria in this dreadful disease, currently considered a disease "of unknown etiology." When my first case of acid-fast bacteria in scleroderma was reported in The Archives, also in 1966, I learned about Virginia Livingston MD, who first reported similar bacteria in scleroderma back in 1947 in the Journal of the Medical Society of New Jersey. CBH: And when did you first become interested in cancer bacteria research? Was your initial interest in cancer bacteria related to skin diseases? Cantwell: When I first met with Virginia (Livingston) in San Diego, I learned of her many years of research into acid-fast "pleomorphic bacteria" that she and her associates had discovered and studied in every case of cancer that they investigated. CBH: As a young physician, were you initially skeptical of the idea of a cancer bacterium? If so, what convinced you that there might be something to the theory? Cantwell: I never believed in my wildest dreams that I would ever study the bacterial cause of cancer. It was inconceivable to me that scientists could have failed to recognize a microscopically visible infectious bacterial agent in cancer. I soon learned that Virginia and her colleagues suffered greatly for their belief and research into the bacterial cause of cancer. For her whole life, Virginia was marginalized and condemned by her colleagues for her attempts to treat cancer patients with vaccines, antibiotics, diet, and supplements. CBH: Were you surprised at your findings from a microbiological standpoint? What I mean is, did your findings clash with the known tenets of microbiology? And if so, can you tell us briefly, how? Cantwell : I must admit that I never studied bacteria in cancer until the mid-1970s. There were two reasons for this. First, I thought that the scleroderma work would be confirmed by other dermatolgists and scientists, and that I would be content to have discovered a cause of that disease. But after a half-century, it is sad to relate that Virginia and I are the only two physicians who have ever presented evidence for this. Secondly, I worked for an HMO and I didn't want to be regarded as a "quack" like Virginia had been labeled, so I avoided the cancer bacteria controvery as long as I could. However, in the mid-1970s I found pleomorphic bacteria in sarcoidosis, and also in a lymphoma that appeared in one of my patients with sarcoidosis. I was amazed to see how easy it was to detect these bacteria in sarcoidosis and lymphoma, and in these two diseases also "of unknown etiology." Once I realized that Virginia was so correct in her declarations of a cancer bacterium, my research progressed rapidly in studying other forms of cancer, as well as immune diseases, like lupus erythematosus. At that point I finally had attained the courage of my convictions, and was willing to take a stand along with Virginia. CBH: Dr. Cantwell, much has been made about bacterial pleomorphism, and you have been one of that phenomena's most knowledgeable investigators. Can you tell us just how pleomorphism might have, and still does, create misunderstanding and confusion among researchers? More- http://rense.com/general74/cant.htm Want to start your own business? Learn how on Small Business. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.